Acadia Revives Nuplazid’s Chances In Schizophrenia With Negative Symptom Data

After a Phase III failure in refractory schizophrenia, Acadia has Phase II data showing efficacy in negative symptoms of the disease, an unmet need. It plans a pivotal study in 2020.